Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.

European journal of gastroenterology & hepatology - 1 Jan 2017

Nordstrom Eric M, Keniston Angela, Baouchi Fafa, Martinez-Camacho Alvaro

Abstract excerpt

AIMS: This study assesses the efficacy, accessibility, and safety of hepatitis C virus (HCV) treatment in a safety net hospital population. METHODS: Patients at Denver Health receiving pegylated interferon for HCV infection between 2008 and 2012 were included in this retrospective study. Sociodemographic, biochemical, and virologic data were collected on each patient. The primary outcomes were the rate of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorado
Share to Health Services Accessibility

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C Antibodies

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Share to Socioeconomic Factors

Share to Sustained Virologic Response

Source

Identifiers

PMID: 27755117
DOI: 10.1097/MEG.0000000000000755

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.PMID 27755117Read ↗

A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapiesSemantic proximity Read ↗

Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.Semantic proximity Read ↗

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.Semantic proximity Read ↗

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV eliminationSemantic proximity Read ↗

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.Semantic proximity Read ↗

Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy: A National Observational Cohort StudySemantic proximity Read ↗

Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.Semantic proximity Read ↗

Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.Semantic proximity Read ↗

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.Semantic proximity Read ↗

High rates of early treatment discontinuation in hepatitis C-infected US veterans.Semantic proximity Read ↗

Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic.Semantic proximity Read ↗

A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.